Pricing Log in Create free account

Fate Therapeutics, Inc. (FATE) vs Lexeo Therapeutics, Inc. (LXEO)

Fate Therapeutics, Inc. and Lexeo Therapeutics, Inc. are both Biotechnology companies. Fate Therapeutics, Inc. and Lexeo Therapeutics, Inc. are of similar size ($230.7M and $226.6M). Lexeo Therapeutics, Inc. has the higher net margin (0.00% vs −1,941.1%) and the lower return on invested capital (−253.5% vs 0.00%). Across the 14 metrics below, Lexeo Therapeutics, Inc. leads on 9 and Fate Therapeutics, Inc. on 5.

Valuation

Metric FATE LXEO Biotechnology median
P/E n/m n/m 8.50
P/S 33.20 n/m 9.71
P/B 1.40 0.96 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 13.12 n/m 9.21
Earnings yield (58.66%) (43.56%) (33.15%)
Free cash flow yield (48.92%) (39.24%) (25.50%)

Profitability

Metric FATE LXEO Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (2,058.08%) 0.00% 0.00%
Net margin (1,941.09%) 0.00% 0.00%
Free cash flow margin (1,624.06%) 0.00% 0.00%
Return on equity (60.75%) (46.76%) (56.36%)
Return on assets (39.89%) (40.50%) (48.04%)
Return on invested capital 0.00% (253.48%) 0.00%

Growth

Metric FATE LXEO Biotechnology median
Revenue growth (TTM) (23.36%) — 6.02%
EPS growth (last fiscal year) 29.88% 39.81% 30.26%
Revenue growth, 5-year CAGR (26.71%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FATE LXEO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.85 13.89 4.72
Net debt to EBITDA 1.47 1.67 0.96

Dividend

Metric FATE LXEO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric FATE LXEO Biotechnology median
Market cap 230.65m 226.56m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack